Citations (39)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Alaa Abu-Mahfouz, Maha Ali & Abdo Elfiky. (2023) Anti-breast cancer drugs targeting cell-surface glucose-regulated protein 78: a drug repositioning in silico study. Journal of Biomolecular Structure and Dynamics 41:16, pages 7794-7808.
Read now
Read now
Mala Sharma, Neha Sharma, Mohd Muddassir, Qazi Inamur Rahman, U. N. Dwivedi & Salman Akhtar. (2022) Structure-based pharmacophore modeling, virtual screening and simulation studies for the identification of potent anticancerous phytochemical lead targeting cyclin-dependent kinase 2. Journal of Biomolecular Structure and Dynamics 40:20, pages 9815-9832.
Read now
Read now
Moataz Ehab & Mohamad Elbaz. (2016) Profile of palbociclib in the treatment of metastatic breast cancer. Breast Cancer: Targets and Therapy 8, pages 83-91.
Read now
Read now
Tatyana S. Nekova, Susanne Kneitz, Hermann Einsele, Ralf Bargou & Gernot Stuhler. (2016) Silencing of CDK2, but not CDK1, separates mitogenic from anti-apoptotic signaling, sensitizing p53 defective cells for synthetic lethality. Cell Cycle 15:23, pages 3203-3209.
Read now
Read now
Articles from other publishers (35)
Gevorg G. Danagulyan, Meline R. Arakelyan, Nicolai A. Aksenov, Henrik A. Panosyan, Armen G. Ayvazyan & Ani H. Hasratyan. (2024) Synthesis of 4-(pyrazol-1-yl)pyrimidines from 4-hydrazinopyrimidines and investigation of their structure and some chemical properties. Journal of Molecular Structure 1295, pages 136676.
Crossref
Crossref
Alessia Bono, Gabriele La Monica, Federica Alamia, Francesco Mingoia, Carla Gentile, Daniele Peri, Antonino Lauria & Annamaria Martorana. (2023) In Silico Mixed Ligand/Structure-Based Design of New CDK-1/PARP-1 Dual Inhibitors as Anti-Breast Cancer Agents. International Journal of Molecular Sciences 24:18, pages 13769.
Crossref
Crossref
Г. Г. Данагулян & В. К. Гарибян. (2023) Спектр биологической активности произ-водных пиразоло[1,5-а]пиримидина и пути их модификации (обзор). Chemical Journal of Armenia, pages 77-103.
Crossref
Crossref
Gevorg G. Danagulyan, Henrik A. Panosyan, Vache K. Gharibyan & Ani H. Hasratyan. (2023) A Simple and Easily Implemented Method for the Regioselective Introduction of Deuterium into Azolo[1,5-a]pyrimidines Molecules. Molecules 28:6, pages 2869.
Crossref
Crossref
Manzoor Ahmad Mir, Aabida Gul, Shazia Sofi & M. Sultan Khan. 2023. Therapeutic potential of Cell Cycle Kinases in Breast Cancer. Therapeutic potential of Cell Cycle Kinases in Breast Cancer
313
333
.
Haichen Zhang, Tong Chu, Jin Zheng, Yun Teng, Ruilan Ma, Lijuan Zou & Haidong Zhao. (2022) Sensitization of cervical cancer cells to radiation by the cyclin-dependent kinase inhibitor dinaciclib. Medical Oncology 40:2.
Crossref
Crossref
Fan Xie, Liying Zhou, Changwei Ge, Xiuqing Song & Hong Yan. (2022) Development of pyrazolo[3,4-d]pyrimidin-4-one scaffold as novel CDK2 inhibitors: Design, synthesis, and biological evaluation. Bioorganic & Medicinal Chemistry Letters 70, pages 128803.
Crossref
Crossref
Farinaz Barghi, Harlan E. Shannon, M. Reza Saadatzadeh, Barbara J. Bailey, Niknam Riyahi, Khadijeh Bijangi-Vishehsaraei, Marissa Just, Michael J. Ferguson, Pankita H. Pandya & Karen E. Pollok. (2022) Precision Medicine Highlights Dysregulation of the CDK4/6 Cell Cycle Regulatory Pathway in Pediatric, Adolescents and Young Adult Sarcomas. Cancers 14:15, pages 3611.
Crossref
Crossref
Qian Yuan, Kui Su, Shuyi Li, Xinyi Long, Lang Liu, Minghui Yang, Xin Yuan, Jianwu Sun, Junhua Hu, Qin Li, Yu Zhao & Zhengqiang Yuan. (2022) Pulmonary Delivery of Extracellular Vesicle-Encapsulated Dinaciclib as an Effective Lung Cancer Therapy. Cancers 14:14, pages 3550.
Crossref
Crossref
Yixuan Ma, Sina Sender, Anett Sekora, Weibo Kong, Peter Bauer, Najim Ameziane, Susann Krake, Mandy Radefeldt, Ruslan Al-Ali, Frank Ulrich Weiss, Markus M. Lerch, Alisha Parveen, Dietmar Zechner, Christian Junghanss & Hugo Murua Escobar. (2022) Inhibitory Response to CK II Inhibitor Silmitasertib and CDKs Inhibitor Dinaciclib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines. International Journal of Molecular Sciences 23:8, pages 4409.
Crossref
Crossref
Deendyal Bhurta & Sandip B. Bharate. (2021) Analyzing the scaffold diversity of cyclin‐dependent kinase inhibitors and revisiting the clinical and preclinical pipeline. Medicinal Research Reviews 42:2, pages 654-709.
Crossref
Crossref
Rinky Raghuvanshi & Sandip B. Bharate. (2021) Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections. Journal of Medicinal Chemistry 65:2, pages 893-921.
Crossref
Crossref
Laura Keren Urbina-Jara, Emmanuel Martinez-Ledesma, Augusto Rojas-Martinez, Francisco Ricardo Rodriguez-Recio & Rocio Ortiz-Lopez. (2021) DNA Repair Genes as Drug Candidates for Early Breast Cancer Onset in Latin America: A Systematic Review. International Journal of Molecular Sciences 22:23, pages 13030.
Crossref
Crossref
Dan Wei, Hanlin Wang, Qinghe Zeng, Wenjing Wang, Bingbing Hao, Xule Feng, Peipei Wang, Ning Song, Weijuan Kan, Guifang Huang, Xiaoyu Zhou, Minjia Tan, Yubo Zhou, Ruimin Huang, Jia Li & Xiao-Hua Chen. (2021) Discovery of Potent and Selective CDK9 Degraders for Targeting Transcription Regulation in Triple-Negative Breast Cancer. Journal of Medicinal Chemistry 64:19, pages 14822-14847.
Crossref
Crossref
Maria Apostolidi, Ioannis A. Vathiotis, Viswanathan Muthusamy, Patricia Gaule, Brandon M. Gassaway, David L. Rimm & Jesse Rinehart. (2021) Targeting Pyruvate Kinase M2 Phosphorylation Reverses Aggressive Cancer Phenotypes. Cancer Research 81:16, pages 4346-4359.
Crossref
Crossref
Mohammad M. Al-Sanea, Ahmad J. Obaidullah, Mohamed E. Shaker, Garri Chilingaryan, Mohammed M. Alanazi, Nawaf A. Alsaif, Hamad M. Alkahtani, Sultan A. Alsubaie & Mohamed A. Abdelgawad. (2021) A New CDK2 Inhibitor with 3-Hydrazonoindolin-2-One Scaffold Endowed with Anti-Breast Cancer Activity: Design, Synthesis, Biological Evaluation, and In Silico Insights. Molecules 26:2, pages 412.
Crossref
Crossref
Ashraf N. Abdalla, Amal Qattan, Waleed H. Malki, Imran Shahid, Mohammad Akbar Hossain & Muhammad Ahmed. (2020) Significance of Targeting VEGFR-2 and Cyclin D1 in Luminal-A Breast Cancer. Molecules 25:20, pages 4606.
Crossref
Crossref
Shahin Hallaj, Sima Heydarzadeh Asl, Fatemeh Alian, Sajjad Farshid, Farzaneh Sadat Eshaghi, Afshin Namdar, Fatemeh Atyabi, Ali Masjedi, Tooba Hallaj, Anahita Ghorbani, Ghasem Ghalamfarsa, Mozhdeh Sojoodi & Farhad Jadidi-Niaragh. (2020) Inhibition of CD73 using folate targeted nanoparticles carrying anti-CD73 siRNA potentiates anticancer efficacy of Dinaciclib. Life Sciences 259, pages 118150.
Crossref
Crossref
Li, Ji, Porter, Broude, Roninson & Chen. (2019) Characterizing CDK8/19 Inhibitors through a NFκB-Dependent Cell-Based Assay. Cells 8:10, pages 1208.
Crossref
Crossref
Huayan Zhao, Shenglei Li, Guannan Wang, Wugan Zhao, Dandan Zhang, Fang Wang, Wencai Li & Ling Sun. (2019)
Study of the mechanism by which dinaciclib induces apoptosis and cell cycle arrest of lymphoma Raji cells through a
CDK1
‐involved pathway
. Cancer Medicine 8:9, pages 4348-4358.
Crossref
Crossref
Astrid Weiss, Moritz Christian Neubauer, Dinesh Yerabolu, Baktybek Kojonazarov, Beate Christiane Schlueter, Lavinia Neubert, Danny Jonigk, Nelli Baal, Clemens Ruppert, Peter Dorfmuller, Soni Savai Pullamsetti, Norbert Weissmann, Hossein-Ardeschir Ghofrani, Friedrich Grimminger, Werner Seeger & Ralph Theo Schermuly. (2019) Targeting cyclin-dependent kinases for the treatment of pulmonary arterial hypertension. Nature Communications 10:1.
Crossref
Crossref
Priscylla Andrade Volkart, Gabriela Bitencourt-Ferreira, André Arigony Souto & Walter Filgueira de Azevedo. (2019) Cyclin-Dependent Kinase 2 in Cellular Senescence and Cancer. A Structural and Functional Review. Current Drug Targets 20:7, pages 716-726.
Crossref
Crossref
Ravindra M. Gol, Taslimahemad T. Khatri & Vijaykumar M. Barot. (2019) Facile Regioselective On-Water Synthesis of 4,7-Dihydropyrazolo[1,5-a]Pyrimidines and 4,7-Dihydro[1,2,4]Triazolo[1,5-a]Pyrimidines. Chemistry of Heterocyclic Compounds 55:3, pages 246-253.
Crossref
Crossref
Eun-Hui Jeong, Tae-Gul Lee, Yun Jung Ko, Seo Yun Kim, Hye-Ryoun Kim, Hyunggee Kim & Cheol Hyeon Kim. (2018) Anti-tumor effect of CDK inhibitors on CDKN2A-defective squamous cell lung cancer cells. Cellular Oncology 41:6, pages 663-675.
Crossref
Crossref
Xiaoxia Hu, Hui Zhao, Youzhi Wang, Zhan Liu, Bainian Feng & Chunlei Tang. (2018) Synthesis and biological evaluation of novel 5,6-dihydropyrimido[4,5-f]quinazoline derivatives as potent CDK2 inhibitors. Bioorganic & Medicinal Chemistry Letters 28:20, pages 3385-3390.
Crossref
Crossref
Ghaneya S Hassan, Hanan H Georgey, Riham F George & Eman R Mohammed. (2018) Construction of some cytotoxic agents with aurone and furoaurone scaffolds. Future Medicinal Chemistry 10:1, pages 27-52.
Crossref
Crossref
C.‐H. Heldin, J. Lennartsson & B. Westermark. (2017) Involvement of platelet‐derived growth factor ligands and receptors in tumorigenesis. Journal of Internal Medicine 283:1, pages 16-44.
Crossref
Crossref
Gary K. Scott, David Chu, Ravneet Kaur, Julia Malato, Daniel E. Rothschild, Katya Frazier, Serenella Eppenberger-Castori, Byron Hann, Ben Ho Park & Christopher C. Benz. (2016) ERpS294 is a biomarker of ligand or mutational ERα activation and a breast cancer target for CDK2 inhibition. Oncotarget 8:48, pages 83432-83445.
Crossref
Crossref
Yu Zhang, Liang Zhou, Yun Leng, Yun Dai, Robert Z. Orlowski & Steven Grant. (2017) Positive transcription elongation factor b (P-TEFb) is a therapeutic target in human multiple myeloma. Oncotarget 8:35, pages 59476-59491.
Crossref
Crossref
Ping Chen, Nathan V. Lee, Wenyue Hu, Meirong Xu, Rose Ann Ferre, Hieu Lam, Simon Bergqvist, James Solowiej, Wade Diehl, You-Ai He, Xiu Yu, Asako Nagata, Todd VanArsdale & Brion W. Murray. (2016) Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance. Molecular Cancer Therapeutics 15:10, pages 2273-2281.
Crossref
Crossref
Zhenghu Chen, Zhenyu Wang, Jonathan C. Pang, Yang Yu, Shayahati Bieerkehazhi, Jiaxiong Lu, Ting Hu, Yanling Zhao, Xin Xu, Hong Zhang, Joanna S. Yi, Shangfeng Liu & Jianhua Yang. (2016) Multiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activity. Scientific Reports 6:1.
Crossref
Crossref
Jason P.W. Carey & Khandan Keyomarsi. (2016) Targeting the Cell Cycle in Breast Cancer. Breast Diseases: A Year Book Quarterly 27:4, pages 256-260.
Crossref
Crossref
Shankar Varadarajan, Paramasivan Poornima, Mateus Milani, Krishne Gowda, Shantu Amin, Hong-Gang Wang & Gerald M. Cohen. (2015) Maritoclax and dinaciclib inhibit MCL-1 activity and induce apoptosis in both a MCL-1-dependent and -independent manner. Oncotarget 6:14, pages 12668-12681.
Crossref
Crossref
Conleth G. MurphyMaura N. Dickler. (2015) The Role of CDK4/6 Inhibition in Breast Cancer. The Oncologist 20:5, pages 483-490.
Crossref
Crossref
Erica L. Mayer. (2015) Targeting Breast Cancer with CDK Inhibitors. Current Oncology Reports 17:5.
Crossref
Crossref